Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade

被引：0
|
作者：
Chiang, A. [1 ]
Matera, R. [1 ]
Ashley, K. [2 ]
Rajendran, B. K. [2 ]
Schalper, K. A. [2 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
SCLC; Tumor Microenvironment; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.13D.07
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 50 条
  • [41] Circulating tumor cells (CTC) as a biomarker of response in patients with extensive-stage small cell lung cancer (EX-SCLC).
    Huang, Chao H.
    Ganti, Apar Kishor
    Neupane, Prakash
    Sittampalam, G. Sitta
    Schmitt, Sarah
    Nirmalanandhan, Sanjit
    Williamson, Stephen K.
    Wick, Jo
    Smart, Janie
    Spencer, Sarah Ellen
    Godwin, Andrew K.
    Van Veldhuizen, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)
    Chae, Young Kwang
    Dietrich, Eliana
    Othus, Megan
    Chung, Liam I. L. Young
    Kim, Hye Sung
    Ryan, Christopher W.
    Blanke, Charles D.
    Patel, Sandip Pravin
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
    Chen, Pei-Ling
    Roh, Whijae
    Reuben, Alexandre
    Cooper, Zachary A.
    Spencer, Christine N.
    Prieto, Peter A.
    Miller, John P.
    Bassett, Roland L.
    Gopalakrishnan, Vancheswaran
    Wani, Khalida
    De Macedo, Mariana Petaccia
    Austin-Breneman, Jacob L.
    Jiang, Hong
    Chang, Qing
    Reddy, Sangeetha M.
    Chen, Wei-Shen
    Tetzlaff, Michael T.
    Broaddus, Russell J.
    Davies, Michael A.
    Gershenwald, Jeffrey E.
    Haydu, Lauren
    Lazar, Alexander J.
    Patel, Sapna P.
    Hwu, Patrick
    Hwu, Wen-Jen
    Diab, Adi
    Glitza, Isabella C.
    Woodman, Scott E.
    Vence, Luis M.
    Wistuba, Ignacio I.
    Amaria, Rodabe N.
    Kwong, Lawrence N.
    Prieto, Victor
    Davis, R. Eric
    Ma, Wencai
    Overwijk, Willem W.
    Sharpe, Arlene H.
    Hu, Jianhua
    Futreal, P. Andrew
    Blando, Jorge
    Sharma, Padmanee
    Allison, James P.
    Chin, Lynda
    Wargo, Jennifer A.
    CANCER DISCOVERY, 2016, 6 (08) : 827 - 837
  • [44] Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
    Hubert, Pascale
    Roncarati, Patrick
    Demoulin, Stephanie
    Pilard, Charlotte
    Ancion, Marie
    Reynders, Celia
    Lerho, Thomas
    Bruyere, Diane
    Lebeau, Alizee
    Radermecker, Coraline
    Meunier, Margot
    Nokin, Marie-Julie
    Hendrick, Elodie
    Peulen, Olivier
    Delvenne, Philippe
    Herfs, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
  • [45] Proteomic biomarker analysis of metastatic melanoma patients treated with anti-PD-1 checkpoint blockade
    Ascierto, Paolo Antonio
    Capone, Mariaelena
    Grimaldi, Antonio Maria
    Mallardo, Domenico
    Simeone, Ester
    Roder, Heinrich
    Meyer, Krista
    Asmellash, Senait
    Oliveira, Carlos
    Roder, Joanna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [46] Reclassifying TNM stage I/II colorectal cancer into two subgroups with different overall survival, tumor microenvironment, and response to immune checkpoint blockade treatment
    Liu, Xiangxiang
    Qin, Jian
    Nie, Junjie
    Sun, Huiling
    Pan, Yuqin
    Wang, Shukui
    FRONTIERS IN GENETICS, 2022, 13
  • [47] A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer
    Bila, Michel
    Van Dessel, Jeroen
    Smeets, Maximiliaan
    Vander Poorten, Vincent
    Nuyts, Sandra
    Meulemans, Jeroen
    Clement, Paul M.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial
    Takada, Kazuki
    Takamori, Shinkichi
    Shimokawa, Mototsugu
    Pinato, David J.
    Cortellini, Alessio
    INTERNATIONAL JOURNAL OF CANCER, 2025, 156 (05) : 914 - 919
  • [49] Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic
    Vilarino, N.
    Bruna, J.
    Bosch-Barrera, J.
    Valiente, M.
    Nadal, E.
    CANCER TREATMENT REVIEWS, 2020, 89
  • [50] Spatial analysis of tumor immune microenvironment (TIME) in patients treated with Bintrafusp alfa.
    Sater, Houssein Abdul
    Robinson, Jeffrey
    Strauss, Julius
    Gatti-Mays, Margaret Elena
    Redman, Jason
    Floudas, Charalampos S.
    Marte, Jenn
    Cordes, Lisa M.
    Rodriguez, Beatriz Walter
    Wiseman, Andrew
    Zaki, George
    Karzai, Fatima
    Bilusic, Marijo
    Madan, Ravi Amrit
    Schlom, Jeffrey
    Rajan, Arun
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345